ANDA 213130, held by Meitheal. Isosulfan Blue.
As of Nov 16, 2026, ANDA 213130 (Isosulfan Blue), held by Meitheal, was first approved by FDA on Nov 3, 2021, with 0 approved supplements and 0 published complete response letters.
Isosulfan Blue Injection 1% upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities. 1.1 Lymphatic Vessel Delineation Isosulfan Blue Injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 3, 2021 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Isosulfan Blue50MG/5ML (10MG/ML) · solution;subcutaneous | Isosulfan Blue | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters